As Alberta endures its worst year for measles since the 1970s, public health nurses from around the world are gathered in ...

If Biodexa's eRapa treatment is shown to be successful in its Phase 3 study and the treatment gets approved, the company believes it would have first-mover advantage in what it estimates is a $7 ...